A
A
Home

Press Releases

2020

argenx announces results of Annual General Meeting of Shareholders
argenx to Present Data from Phase 2 Trial of Efgartigimod in Pemphigus at 2020 Society for Investigative Dermatology (SID) Virtual Annual Meeting
argenx to report first quarter 2020 financial results and business update on May 14, 2020
argenx to Present at BofA Securities Virtual Health Care Conference 2020
March 31, 2020
argenx announces Annual General Meeting of Shareholders on May 12, 2020
argenx full year 2019 financial results
February 24, 2020
argenx to Present at Cowen 40th Annual Health Care Conference
February 19, 2020
argenx to report full year 2019 financial results and fourth quarter business update on February 27, 2020
January 8, 2020
argenx Provides Strategic Outlook Advancing Late-Stage Pipeline Towards ‘argenx 2021’ Vision

2019

argenx announces publication of efgartigimod Phase 2 primary immune thrombocytopenia trial results in American Journal of Hematology
December 6, 2019
argenx Announces Receipt of First Milestone Payment under Janssen Collaboration and Provides Data Update from Phase 1 Dose Escalation Trial of Cusatuzumab in Acute Myeloid Leukemia at ASH Annual Meeting
November 25, 2019
argenx Announces Upcoming Investor Events